TNFRSF8 and neoplasm: Other immunotherapies targeting CD30 are being developed, including T cells with engineered expression of chimeric antigen receptors (CARs) (16–18) and anti-CD30 x anti-CD16A bispecific antibodies (biAbs) to engage NK cells and target tumor cells (19, 20).